Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study

被引：14
|
作者：
Jones, Jeffrey [1 ]
Andritsos, Leslie [2 ]
Kreitman, Robert J. [3 ]
Ravandi, Farhad [4 ]
Schiffer, Charles [5 ]
Call, Timothy G. [6 ]
Lozanski, Gerard [7 ]
Harris, Pamela [8 ]
Sexton, Jennifer [2 ]
Ruppert, Amy S. [2 ]
Grever, Michael R. [2 ]
机构：
[1] Ohio State Univ, Div Hematol, Dept Internal Med, Columbus, OH USA
[2] Ohio State Univ, Div Hematol, Columbus, OH USA
[3] Natl Canc Inst, Natl Inst Hlth, Mol Biol Lab, Bethesda, MD USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[5] Barbara Ann Karmanos Canc Inst, Detroit, MI USA
[6] Mayo Clin, Div Hematol, Rochester, MN USA
[7] Ohio State Univ, Dept Pathol, Columbus, OH USA
[8] Natl Canc Inst, Canc Therapy Evaluat Program, Rockville, MD USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.1215.1215
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1215
引用
收藏
页数：5
相关论文
共 50 条
  • [1] SAFETY AND EFFICACY OF THE BRUTON TYROSINE KINASE INHIBITOR IBRUTINIB IN PATIENTS WITH HAIRY CELL LEUKEMIA: INTERIM RESULTS OF A PHASE 2 STUDY
    Jones, J. A.
    Andritsos, L.
    Ravandi, F.
    Kreitman, R. J.
    Schiffer, C.
    Call, T.
    Lozanski, G.
    Sexton, J.
    Harris, P.
    Grever, M. R.
    HAEMATOLOGICA, 2015, 100 : 313 - 313
  • [2] Preliminary safety and efficacy of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (IBR) in patients (pts) with hairy cell leukemia (HCL).
    Jones, Jeffrey Alan
    Andritsos, Leslie A.
    Lucas, David M.
    Lozanski, Gerard
    Hutchinson, Terri
    Sexton, Jennifer L.
    Harris, Pamela Jo
    Grever, Michael R.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia
    Brown, Jennifer R.
    Barrientos, Jacqueline C.
    Barr, Paul M.
    Flinn, Ian W.
    Burger, Jan A.
    Anh Tran
    Clow, Fong
    James, Danelle F.
    Graef, Thorsten
    Friedberg, Jonathan W.
    Rai, Kanti
    O'Brien, Susan
    BLOOD, 2015, 125 (19) : 2915 - 2922
  • [4] Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study
    Cooper, Nichola
    Jansen, A. J. Gerard
    Bird, Robert
    Mayer, Jiri
    Sholzberg, Michelle
    Tarantino, Michael D.
    Garg, Mamta
    Ypma, Paula F.
    Mcdonald, Vickie
    Percy, Charles
    Kostal, Milan
    Goncalves, Isaac
    Bogdanov, Lachezar H.
    Gernsheimer, Terry B.
    Diab, Remco
    Yao, Mengjie
    Daak, Ahmed
    Kuter, David J.
    AMERICAN JOURNAL OF HEMATOLOGY, 2025, 100 (03) : 439 - 449
  • [5] INITIAL REPORT OF PART B PHASE 1/2 EFFICACY AND SAFETY RESULTS FOR BRUTON TYROSINE KINASE INHIBITOR RILZABRUTINIB IN PATIENTS WITH RELAPSED IMMUNE THROMBOCYTOPENIA
    Cooper, Nichola
    Jansen, A. J. Gerard
    Mayer, Jiri
    Tarantino, Michael D.
    Diab, Remco
    Ward, Brad
    Daak, Ahmed
    Kuter, David J.
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 100 : 29 - 29
  • [6] Effects of the Bruton's tyrosine kinase inhibitor ibrutinib on humoral immunity in patients with chronic lymphocytic leukemia
    Sun, Clare
    Lee, Yuh Shan
    Lipsky, Andrew
    Farooqui, Mohammed
    Herman, Sarah
    Salem, Dalia
    Stetler-Stevenson, Maryalice
    Yuan, Constance
    Aue, Georg
    Wiestner, Adrian
    JOURNAL OF IMMUNOLOGY, 2015, 194
  • [7] Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies
    Marostica, Eleonora
    Sukbuntherng, Juthamas
    Loury, David
    de Jong, Jan
    de Trixhe, Xavier Woot
    Vermeulen, An
    De Nicolao, Giuseppe
    O'Brien, Susan
    Byrd, John C.
    Advani, Ranjana
    McGreivy, Jesse
    Poggesi, Italo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (01) : 111 - 121
  • [8] Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia
    Barrientos, Jacqueline
    Rai, Kanti
    LEUKEMIA & LYMPHOMA, 2013, 54 (08) : 1817 - 1820
  • [9] A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors
    Hong, David
    Rasco, Drew
    Veeder, Michael
    Luke, Jason J.
    Chandler, Jason
    Balmanoukian, Ani
    George, Thomas J.
    Munster, Pamela
    Berlin, Jordan D.
    Gutierrez, Martin
    Mita, Alain
    Wakelee, Heather
    Samakoglu, Selda
    Guan, Shanhong
    Dimery, Isaiah
    Graef, Thorsten
    Borazanci, Erkut
    ONCOLOGY, 2019, 97 (02) : 102 - 111
  • [10] Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies
    Eleonora Marostica
    Juthamas Sukbuntherng
    David Loury
    Jan de Jong
    Xavier Woot de Trixhe
    An Vermeulen
    Giuseppe De Nicolao
    Susan O’Brien
    John C. Byrd
    Ranjana Advani
    Jesse McGreivy
    Italo Poggesi
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 111 - 121
12345